MET and non-small cell lung carcinoma: Recently, several selective MET-targeted small-molecule TKIs have been developed, of which three – tepotinib hydrochloride hydrate (hereafter “tepotinib”), capmatinib, and savolitinib – have been approved on the basis of clinical benefit for patients with advanced/metastatic NSCLC harboring METex14 skipping alterations (26, 27).